



ASPEN PHARMACARE HOLDINGS LIMITED  
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)  
Registration number 1985/0002935/06  
Share code: APN  
ISIN: ZAE000066692  
And its subsidiaries (collectively “Aspen” or “the Group”)

## **VOLUNTARY ANNOUNCEMENT REGARDING THE COMPLETION OF A TRANSACTION WITH GSK IN RESPECT OF THE ACQUISITION OF A PORTFOLIO OF ANAESTHETICS**

Shareholders are referred to the announcement released by Aspen Holdings on 12 September 2016 wherein it was confirmed, *inter alia*, that Aspen Global Incorporated (“AGI”) had signed an agreement with GSK in terms whereof AGI would acquire a portfolio of anaesthetics globally (with the exception of certain territories, primarily North America) (“the Anaesthetics Transaction”). In consideration for the Anaesthetics Transaction AGI would pay an initial amount of £180 million and further milestone payments of up to £100 million, based on the results of the acquired portfolio in the 36 months following completion.

Aspen Holdings is pleased to announce that this transaction completed on 28 February 2017.

### **Durban**

1 March 2017

### **Sponsor:**

Investec Bank Limited

### **About Aspen**

Aspen is a leading global player in specialty, branded and generic pharmaceuticals with an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. Aspen continues to increase the number of lives benefitting from its products, reaching more than 150 countries.

Aspen has a strong presence in both emerging and developed countries. Its emerging market footprint includes Sub-Saharan Africa, Latin America, South East Asia, China, Eastern Europe and the Commonwealth of Independent States, comprising Russia and the former Soviet Republics. From a developed world perspective Aspen is one of the leading pharmaceutical companies in Australia and has a growing presence in other developed countries, most notably in Western Europe.

Aspen operates with an established business presence in approximately 50 countries spanning 6 continents and employs more than 10,000 people. The Group operates 26 manufacturing facilities across 18 sites. Aspen holds international manufacturing approvals from some of the most stringent global regulatory agencies including the FDA, TGA and EMA. Aspen’s manufacturing capabilities are scalable to demand and cover a wide variety of product-types including oral solid dose, liquids, semi-solids, steriles, biologicals, APIs and infant nutritionals.

Aspen, with a market capitalisation of approximately \$10 billion, is the largest pharmaceutical company listed on the JSE Limited (share code: APN) and ranks amongst the top 20 listed companies on this exchange. For more information visit: <http://www.aspenpharma.com/>